Journal of Hebei Medical University ›› 2023, Vol. 44 ›› Issue (6): 640-644.doi: 10.3969/j.issn.1007-3205.2023.06.004

Previous Articles     Next Articles

Effects of transcutaneous electrical facial nerve stimulation combined with botulinum toxin type A on neurophysiology, sleep and recurrence in patients with lateral facioscapulohumeral spasm

  

  1. The Fourth Department of Neurology, Handan Central Hospital, Hebei Province, Handan 56002, China

  • Online:2023-06-25 Published:2023-06-29

PDF (PC)

129

Abstract: Objective To compare the clinical efficacy of transcutaneous electricalfacial nerve stimulation combined with botulinum toxin type A in patients with hemifacial spasm (HFS). 
Methods A total of 80 patients with HFS were selected and divided into control group (n=40) and observation group (n=40) according to random number table method. The control group was given repeated injection of botulinum toxin type A, and the observation group was given repeated injection of botulinum toxin type A + transcutaneous electrical facial nerve stimulation. The time to onset, time to spasm remission, incidence of adverse reactions and recurrence rates of the two groups were compared, and the degree of spasticity, neurophysiology (complex muscle action potential, blink reflex), and sleep quality ［Pittsburgh sleep quality index (PSQI)］ before and after treatment were compared. 
Results The time to onset was shorter in the observation group than in the control group, while time to spasm remission in the observation group was longer than that in the control group (P＜0.05). After treatment, the improvement of spasticity was better than that before treatment, and better in the observation group than in the control group (P＜0.05). After treatment, the compound muscle action potential of the two groups was higher than that before treatment, and higher in the observation group than in the control group, and the blink reflex R1, R2, and R2′ amplitudes were lower than those before treatment, and lower in the observation group than in the control group (P＜0.05). The PSQI score was lower in both groups than that before treatment, and lower in the observation group than in the control group after treatment (P＜0.05). There was no significant difference in the incidence of adverse reactions and recurrence rates between two groups (P＞0.05). 
Conclusion Transcutaneous electrical facial nerve stimulation combined with botulinum toxin type A is safe and effective in the treatment of HFS patients, and can improve the spastic symptoms, nerve function and sleep quality of patients.


Key words: unilateral facial spasms, botulinum toxin type A, transcutaneous electrical facial nerve stimulation